Arax Advisory Partners
XENE icon

Arax Advisory Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Arax Advisory Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.8K Buy
533
+92
+21% +$5.46K ﹤0.01% 4022
2026
Q2 		$26.6K Buy
+441
New +$24.5K ﹤0.01% 3761
2026
Q1 		– Sell
-27
Closed -$1.21K – 4380
2025
Q4 		$1.21K Sell
27
-92
-77% -$3.86K ﹤0.01% 3436
2025
Q3 		$4.78K Buy
+119
New +$4.19K ﹤0.01% 2886
2024
Q4 		– Sell
-3
Closed -$119 – 2781
2024
Q3 		$119 Hold
3
– – ﹤0.01% 2547
2024
Q2 		$117 Buy
+3
New +$120 ﹤0.01% 2482

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

Arax Advisory Partners's XENE Position: Q3 2026 in Review

Arax Advisory Partners increased its Xenon Pharmaceuticals (XENE) stake by 21% in Q3 2026, buying an estimated $5.46K and bringing the position to 533 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Arax Advisory Partners first reported a position in XENE in Q2 2024 and has held it in 6 quarters since. The position peaked at $26.6K in Q2 2026. 196 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Arax Advisory Partners held 533 shares of Xenon Pharmaceuticals worth $19.8K as of Q3 2026.
  • Arax Advisory Partners bought 92 Xenon Pharmaceuticals shares in Q3 2026, an estimated $5.46K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4022 holding.
  • Arax Advisory Partners first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Xenon Pharmaceuticals position peaked at $26.6K in Q2 2026.
  • 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.